A Novel Treatment Option for Distributive Shock (Non-CE Presentation)
John Devin, Pharm.D., FCCM, FCCP, BCCP
Critical Care Pharmacist and Clinical Scientist
Tufts Medical Center
Tuesday, July 31, 2018
2280 U.S. Hwy 9 South
Old Bridge, NJ 08857
6:30 PM sign in (must pre-register)
- Describe the importance of maintaining a MAP > 65 mmHg in patients with distributive shock
- Distinguish the pharmacology and pharmacokinetics of angiotensin II with norepinephrine and vasopressin
- Describe the primary and secondary efficacy and safety results of the ATHOS-3 trial
- Develop a plan for the appropriate initiation and monitoring of angiotensin II in a patient with distributive/septic shock
This program is sponsored by: La Jolla Pharmaceuticals.
This is not an independent educational program, and no CME credits will be provided.